Aptose Biosciences Inc.
DelistedCIK 882361fmd_0P1WP5JHZ46NACYX4PK996B5BXManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Mar 31, 2026, 39 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Net income
- (25)
- Free cash flow
- (22)
Latest quarter · Q1 FY2026
Millions- Total revenues
- 0
- Net income
- (8)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- n/m
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Aptose Biosciences Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 10-K 2026-03-31 · proof | |
| Net income | -$25.5 million | -$25.4 million | 10-K 2026-03-31 · proof | |
| Cash from operating activities | -$22 million | -$36 million | 10-K 2026-03-31 · proof | |
| Free cash flow | -$22 million | -$36 million | 10-K 2026-03-31 · proof | |
| Total assets | $10 million | $10.1 million | -1.1% | 10-K 2026-03-31 · proof |
| Total liabilities | $37.2 million | $14.7 million | +153.4% | 10-K 2026-03-31 · proof |
| Cash and cash equivalents | $935,000 | $6.2 million | -84.8% | 10-K 2026-03-31 · proof |
- What was Aptose Biosciences Inc.'s revenue in fiscal 2025?
- Aptose Biosciences Inc. reported revenue of $0 for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Aptose Biosciences Inc.'s net income in fiscal 2025?
- Aptose Biosciences Inc. reported net income of -$25.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$25.4 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Aptose Biosciences Inc.'s cash from operating activities in fiscal 2025?
- Aptose Biosciences Inc. reported cash from operating activities of -$22 million for fiscal 2025 (the year ended Dec 31, 2025), against -$36 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Aptose Biosciences Inc.'s free cash flow in fiscal 2025?
- Aptose Biosciences Inc. reported free cash flow of -$22 million for fiscal 2025 (the year ended Dec 31, 2025), against -$36 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Aptose Biosciences Inc.'s total assets?
- As of Dec 31, 2025, Aptose Biosciences Inc. reported total assets of $10 million, against $10.1 million a year earlier (-1.1%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Aptose Biosciences Inc.'s total liabilities?
- As of Dec 31, 2025, Aptose Biosciences Inc. reported total liabilities of $37.2 million, against $14.7 million a year earlier (+153.4%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Aptose Biosciences Inc.'s cash and cash equivalents?
- As of Dec 31, 2025, Aptose Biosciences Inc. reported cash and cash equivalents of $935,000, against $6.2 million a year earlier (-84.8%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:882361&period_type=annual&limit=5"Information only, not investment advice.